A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390 · tracked via the Priya Life Science Spain tracker

Sponsor

Eli Lilly and Company

Phase

Phase 3

Started

2025-12-01

Last updated

2026-09-22

Condition(s) studied

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

Investigational drug(s) / intervention(s)

Orforglipron →Placebo

Orforglipron: Administered orally

Placebo: Administered orally

Study summary

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Eligibility

Sex

ALL

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Have established ASCVD and/or CKD Exclusion Criteria: * Have type 1 diabetes * Have had a major heart condition within 60 days prior to screening * Have New York Heart Association Functional Classification Class IV heart failure

Primary outcome measure(s)

Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events — Baseline up to end of study (about 5 years)
Composite endpoint includes nonfatal myocardial infarction, nonfatal stroke, hospitalization or urgent visit due to heart failure, coronary revascularization, or all-cause death

Trial sites (568)

Facility	City	Region	Status
Instituto de Investigaciones Clínicas Bahia Blanca	Bahía Blanca	Argentina	Recruiting
CONEXA Investigacion Clinica S.A.	Buenos Aires	Argentina	Recruiting
Buenos Aires Macula S.A	Buenos Aires	Argentina	Recruiting
CIPREC	Buenos Aires	Argentina	Recruiting
Instituto Médico Especializado (IME)	Buenos Aires	Argentina	Recruiting
Cicemo Srl	Buenos Aires	Argentina	Recruiting
Cardiología Palermo	Buenos Aires	Argentina	Recruiting
Consultorio Medico Investigador Principal Dr Besada	Buenos Aires	Argentina	Recruiting
Glenny Corp. S.A.	Buenos Aires	Argentina	Recruiting
Organizacion Medica de Investigacion	Buenos Aires	Argentina	Recruiting
Stat Research S.A.	Buenos Aires	Argentina	Recruiting
Investigaciones Medicas Imoba Srl	Buenos Aires	Argentina	Recruiting
Centro de Investigaciones Metabólicas (CINME)	Buenos Aires	Argentina	Recruiting
CIPREC	Buenos Aires	Argentina	Recruiting
Centro Médico Viamonte	Buenos Aires	Argentina	Recruiting
Mautalen Salud e Investigación	Buenos Aires	Argentina	Recruiting
CEMEDIC	Buenos Aires	Argentina	Recruiting
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada	Buenos Aires	Argentina	Recruiting
Fundación Respirar	Buenos Aires	Argentina	Recruiting
CEMEDIAB	C.a.b.a.	Argentina	Recruiting
CEDIC	CABA	Argentina	Recruiting
Instituto de Cardiología "Juana F. Cabral"	Corrientes	Argentina	Recruiting
Centro Diabetológico Dr. Waitman	Córdoba	Argentina	Recruiting
Instituto de Investigaciones Clínicas Córdoba	Córdoba	Argentina	Recruiting
Centro Medico Privado San Vicente Diabetes	Córdoba	Argentina	Recruiting
Instituto Médico DAMIC	Córdoba	Argentina	Recruiting
Hospital Italiano de Córdoba	Córdoba	Argentina	Recruiting
Sanatorio Esperanza	Esperanza	Argentina	Recruiting
CIPADI - Centro Integral de Prevencion y Atencion en Diabetes	Godoy Cruz	Argentina	Recruiting
Centro de Investigaciones Clínicas Baigorria	Granadero Baigorria	Argentina	Recruiting
Centro de Salud Renal Junín	Junín	Argentina	Recruiting
CIMeL	Lanus	Argentina	Recruiting
Centro de Investigaciones Médicas Mar del Plata	Mar del Plata	Argentina	Recruiting
Instituto de Investigaciones Clínicas Mar del Plata	Mar del Plata	Argentina	Recruiting
Instituto de Cardiología Wolff	Mendoza	Argentina	Recruiting
CER medical Institute	Quilmes	Argentina	Recruiting
DIM Clínica Privada	Ramos Mejía	Argentina	Recruiting
Instituto Médico Río Cuarto	Río Cuarto	Argentina	Recruiting
Fundacion Estudios Clinicos	Rosario	Argentina	Recruiting
Fundación Innovaciencia	Rosario	Argentina	Recruiting

+ 528 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in Spain

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Active, not recruiting

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Active, not recruiting

A Study of Brenipatide in Adult Participants With Major Depressive Disorder Recruiting

Other trials for the same condition

Pathways to Equitable Access to Kidney Transplantation in Spain: A Transformative Mixed-methods Study Protocol Starting soon

Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles. Recruiting

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria Active, not recruiting

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors Starting soon

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07241390 on ClinicalTrials.gov ↗ ← All trials in Spain